Abivax S.A.

NASDAQ:ABVX

Biotechnology

Healthcare
$83.83 -0.61%

-$0.62 today

Market cap
$7.34B
Beta
-0.20
P/E (TTM)
-18.1
EPS (TTM)
-$4.83
52W Low $5.69High $148.83

Volume 1.19M

Average 1.59M

ABVX Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Abivax S.A.NASDAQ: ABVX

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization grows 49.0% year over year

Q2 FY2026 depreciation & amortization of €374K rose 49.0% year over year. Over 3 fiscal years it compounded at +30.3% a year.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
€374K— QoQ
Last fiscal yearDec 2025
€1.07M-2.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+49.0%——
1 year-2.5%——
3-year CAGR+30.3%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

EUR · from the income statement

Latest · FY2025
1.07M EUR
Year-over-year change
-2.5%
4-year CAGR
+37.3%

Depreciation & Amortization vs competitors

How ABVX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -2.5% is the 6th highest of 10, against a peer median of +0.0%.
  • Over three fiscal years its annual growth of +30.3% compares with a peer median of +19.5%.
ABVX Competitors
Depreciation & Amortization for ABVX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$14.4M USD-22.3%+20.4%2.1%
RCUSArcus Biosciences, Inc.LTM Jun 2026$10M USD+0.0%+18.6%8.5%
ANNXAnnexon, Inc.LTM Mar 2026$3.06M USD+36.2%+7.2%—
IVAInventiva S.A.FY2025€2.8M EUR-46.2%+47.6%62.4%
ANABAnaptysBio, Inc.LTM Mar 2026$2.43M USD+1.2%+1.2%1.0%
ABVXAbivax S.A.FY2025€1.07M EUR-2.5%+30.3%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$528K USD+7.3%-17.1%6.3%
IMMXImmix Biopharma, Inc.LTM Mar 2026$398.22K USD+164.2%+454.8%—
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$226K USD-16.3%+27.5%383.1%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$65K USD-99.3%-43.3%0.0%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$0 USD—+72.0%0.0%
Peer median (excluding ABVX) —+0.0%+19.5%4.2%

Competitors are the stored peer set for ABVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue45.52M50.76M000
Gross Profit(45.52M)(50.76M)000
Gross Margin—————
Research & Development47.78M48.3M103.18M146.53M177.76M
Selling, General & Admin5.58M7.49M28.82M38.9M72.87M
Operating Expenses(4.12M)14.07M127.38M172.98M246.06M
Depreciation & Amortization302K485K707K1.1M1.07M
EBITDA(38.59M)(53.32M)(133.21M)(162.71M)(300.7M)
EBITDA Margin—————
Operating Income(41.4M)(64.84M)(127.38M)(172.98M)(246.06M)
Operating Margin—————
Interest Income002.77M8.96M5.75M
Interest Expense3.56M6.94M13.83M12.43M28.48M
Other Income / Expenses(1.05M)4.1M(20.36M)(3.26M)(84.2M)
Income Before Tax(42.45M)(60.74M)(147.74M)(176.24M)(330.25M)
Pre-Tax Margin—————
Income Tax Expense00005.85M
Net Income(42.45M)(60.74M)(147.74M)(176.24M)(336.1M)
Net Margin—————
EPS (Basic)(2.75)(3.18)(3.43)(2.80)(4.65)
EPS (Diluted)(2.75)(3.18)(3.43)(2.80)(4.65)
Weighted Avg Shares15.46M19.09M43.07M63.05M69.53M
Weighted Avg Shares (Diluted)15.46M19.09M43.07M63.05M69.53M

Abivax S.A.

NASDAQ:ABVX

Intrinsic Alpha fair value

Locked

Current Price

$83.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.